NO954576L - AMPA antagonister og en fremgangsmåte til behandling med dem - Google Patents

AMPA antagonister og en fremgangsmåte til behandling med dem

Info

Publication number
NO954576L
NO954576L NO954576A NO954576A NO954576L NO 954576 L NO954576 L NO 954576L NO 954576 A NO954576 A NO 954576A NO 954576 A NO954576 A NO 954576A NO 954576 L NO954576 L NO 954576L
Authority
NO
Norway
Prior art keywords
alkyl
hydrogen
treating
benzyl
phenyl
Prior art date
Application number
NO954576A
Other languages
English (en)
Other versions
NO954576D0 (no
NO305287B1 (no
Inventor
Frank Watjen
Joergen Drejer
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK55893A external-priority patent/DK55893D0/da
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of NO954576D0 publication Critical patent/NO954576D0/no
Publication of NO954576L publication Critical patent/NO954576L/no
Publication of NO305287B1 publication Critical patent/NO305287B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO954576A 1993-05-13 1995-11-13 AMPA antagonister NO305287B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK55893A DK55893D0 (da) 1993-05-13 1993-05-13 Nye receptoraktive forbindelser, deres fremstilling og anvendelse
DK13894 1994-02-02
PCT/EP1994/001492 WO1994026747A1 (en) 1993-05-13 1994-05-09 Ampa antagonists and a method of treatment therewith

Publications (3)

Publication Number Publication Date
NO954576D0 NO954576D0 (no) 1995-11-13
NO954576L true NO954576L (no) 1996-01-15
NO305287B1 NO305287B1 (no) 1999-05-03

Family

ID=26063386

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954576A NO305287B1 (no) 1993-05-13 1995-11-13 AMPA antagonister

Country Status (13)

Country Link
EP (1) EP0698025B1 (no)
JP (1) JP3439215B2 (no)
AT (1) ATE161259T1 (no)
AU (1) AU679075B2 (no)
CA (1) CA2161783C (no)
DE (1) DE69407407T2 (no)
DK (1) DK0698025T3 (no)
ES (1) ES2111930T3 (no)
FI (1) FI954965L (no)
GR (1) GR3026008T3 (no)
NO (1) NO305287B1 (no)
NZ (1) NZ267081A (no)
WO (1) WO1994026747A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
AU4423496A (en) * 1995-03-14 1996-10-02 Warner-Lambert Company Novel glutamate (ampa/kainate) receptor antagonists: n-substituted fused azacycloalkylquinoxalinediones
US5654303A (en) * 1995-06-07 1997-08-05 Warner-Lambert Company Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5566694A (en) * 1995-06-07 1996-10-22 Allegheny Plastics, Inc. Continuous pickling tank with expandable seals
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5874426A (en) * 1995-06-07 1999-02-23 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5614508A (en) * 1995-06-07 1997-03-25 Warner-Lambert Company Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
ZA9711274B (en) * 1996-12-16 1998-06-23 Warner Lambert Co Tricyclic quinoxaline derivatives as neuroprotective agents.
US6172065B1 (en) 1997-03-04 2001-01-09 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
EP1066037B1 (en) * 1998-03-31 2004-12-29 Neurosearch A/S Use of indole-2,3-dione-3-oxime derivatives as ampa antagonists
US6096744A (en) * 1998-05-04 2000-08-01 Warner-Lambert Company Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
DK1183025T3 (da) 1999-05-19 2009-05-04 Painceptor Pharma Corp Hæmmere af proton-styrede kationskanaler og deres anvendelse til behandling af iskæmiske lidelser
EP1255734B1 (en) * 2000-01-24 2006-06-21 NeuroSearch A/S Isatine derivatives with neurotrophic activity
DE10121215A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
WO2007059608A1 (en) * 2005-11-23 2007-05-31 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
CA2652307A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK146787A (da) * 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
MX9204914A (es) * 1991-08-28 1993-07-01 Frank Watjen Nuevos derivados de isatinoxima, metodo para su preparacion y composicion farmaceutica que los comprende.
ATE157977T1 (de) * 1992-10-13 1997-09-15 Warner Lambert Co Chinoxalinderivate als eaa antagonisten

Also Published As

Publication number Publication date
DK0698025T3 (da) 1998-08-24
FI954965A7 (fi) 1995-11-10
NZ267081A (en) 1997-11-24
AU679075B2 (en) 1997-06-19
AU6926494A (en) 1994-12-12
FI954965A0 (fi) 1995-10-18
ATE161259T1 (de) 1998-01-15
JP3439215B2 (ja) 2003-08-25
DE69407407T2 (de) 1998-04-09
JPH08510221A (ja) 1996-10-29
EP0698025A1 (en) 1996-02-28
EP0698025B1 (en) 1997-12-17
NO954576D0 (no) 1995-11-13
WO1994026747A1 (en) 1994-11-24
FI954965L (fi) 1995-11-10
DE69407407D1 (de) 1998-01-29
ES2111930T3 (es) 1998-03-16
CA2161783C (en) 2006-08-15
CA2161783A1 (en) 1994-11-24
GR3026008T3 (en) 1998-04-30
NO305287B1 (no) 1999-05-03

Similar Documents

Publication Publication Date Title
NO954576D0 (no) AMPA antagonister og en fremgangsmåte til behandling med dem
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
NO931151L (no) Fremgangsmaate for fremstilling av nitrogenholdige heterocykliske forbindelser med kondenserte ringer
DK0640065T3 (da) Trisubstituerede phenylderivater som phosphodiesteraseinhibitorer og fremgangsmåder til deres fremstilling
NO20005881L (no) Heterocykliske forbindelser og metoder for å behandle kardialsvikt og andre sykdommer
NO20014363D0 (no) 4-okso-4,7-dihydro-tieno[2,3-b]pyridin-5-karboksamider som antivirale midler
DE60107435D1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
NZ514037A (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders
DE59710816D1 (de) Neue thiazol-derivate mit phosphodiesterase inhibierender wirkung
DK534381A (da) Fremgangsmaade til fremstilling af 2-oxoazetidinderivater
DK452687D0 (da) Dihydropyridinforbindelser, isomere, isomerblandinger, optiske antipoder og racemater deraf, deres fremstilling og anvendelse som laegemidler
ATE224372T1 (de) Substituierte 6-alkylphenanthridine
HUP9700955A2 (hu) Szubsztituált 2-naftoil-guanidin-származékok, előállításuk, valamint az e vegyületeket tartalmazó gyógyszerkészítmények
HUP9903893A2 (hu) Eljárás szívelégtelenségnek ciklopentánnal kondenzált heterogyűrűs endotelin-antagonistákkal történő kezelésére
ATE237611T1 (de) Cyclische harnstoff- und lactamderivate von benzo(5,6)cycloheptapyridinen zur verwendung als farnesyl-protein-transferase-hemmer
SE9701682D0 (sv) Compounds
HUP9900748A1 (hu) Pirrolidinszármazékok alkalmazása alkoholizmus kezelésére alkalmas gyógyszerkészítmények előállítására
DE69915471D1 (de) Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
DE3680807D1 (de) Dioxolobenzisoxazolderivate und verfahren zu ihrer herstellung.
DE3770481D1 (de) Verwendung von imidazochinazolinen zur behandlung und verhinderung von nephritis.
TW200718699A (en) Fused bicycloheterocycle substituted quinuclidine derivatives
TH18165A (th) สารยับยั้งการเกิดคีโมแทกซิของอีโอซีโนฟีล

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees